Diabetic ketoacidosis and mortality in COVID-19 infection

J. S. Stevens, M. M. Bogun, D. J. McMahon, J. Zucker, P. Kurlansky, S. Mohan, M. T. Yin, T. L. Nickolas, U. B. Pajvani

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Aim: - Patients with diabetes have increased morbidity and mortality from COVID-19. Case reports describe patients with simultaneous COVID-19 and diabetic acidosis (DKA), however there is limited data on the prevalence, predictors and outcomes of DKA in these patients. Methods: - Patients with COVID-19 were identified from the electronic medical record. DKA was defined by standardized criteria. Proportional hazard regression models were used to determine risk factors for, and mortality from DKA in COVID-19. Results: - Of 2366 patients admitted for COVID-19, 157 (6.6%) patients developed DKA, 94% of whom had antecedent type 2 diabetes, 0.6% had antecedent type 1 diabetes, and 5.7% patients had no prior diagnosis of diabetes. Patients with DKA had increased hospital length of stay and in-patient mortality. Higher HbA1c predicted increased risk of incident DKA (HR 1.47 per 1% increase, 95% CI 1.40–1.54). Risk factors for mortality included older age (HR 1.07 per 5 years, 95% CI 1.06–1.08) and need for pressors (HR 2.33, 95% CI 1.82–2.98). Glucocorticoid use was protective in patients with and without DKA. Conclusion: - The combination of DKA and COVID-19 is associated with greater mortality, driven by older age and COVID-19 severity.

Original languageEnglish
Article number101267
JournalDiabetes and Metabolism
Volume47
Issue number6
DOIs
StatePublished - Nov 2021

Keywords

  • Coronavirus
  • COVID-19
  • Diabetic ketoacidosis, DKA
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'Diabetic ketoacidosis and mortality in COVID-19 infection'. Together they form a unique fingerprint.

Cite this